Notably, depleting FoxP3+ Tregs in myeloma-inoculated mice reinstated immunological recognition of the oncogenic cells and facilitated tumor remission—with Treg-specific ablation of IFNAR recapitulating this very effect. This evidence concerns the gene IFNAR1 and plasma cell myeloma.